Nestlé SA

TUESDAY, Feb. 3, 2026 — Several baby formula brands are pulling products from stores after France lowered the allowed level of a toxin that can cause nausea, vomiting and diarrhea. On Monday, French companies Popote and Vitagermine removed five batches of infant formula following the rule change. Popote recalled two lots, while Vitagermine pulled three, saying it acted to “better ensure the safety of infants.” The move follows a wave of formula recalls across more than 60 countries since December, involving major manufacturers such as Nestlé, Danone and Lactalis amid concerns that the products could be contaminated with cereulide, a toxin made by certain bacteria. France’s agriculture ministry last week cut the acceptable daily exposure to cereulide, from 0.03 to 0.014 micrograms per kilogram of body weight. That new limit matches a maximum offered this week by the European Food Safety Authority, which said the change is meant to help officials decide when products should be removed “as a precautionary public health measure.” The updated maximum translates to 0.054 micrograms of cereulide per liter of infant formula, Yahoo reported. Vitagermine said its products met earlier, less strict standards but were pulled once the rules changed. Popote said it removed its formula without waiting for the new European regulations. So far, no direct link has been confirmed between the recalled formulas and the deaths of two infants in France in December and January. Authorities are still investigating, however. Some advocates say even small amounts of cereulide should not be tolerated. "Cereulide should not be there at all in the first place," Foodwatch , a European consumer group, arguing that baby products should never expose infants to health risks. The recalls have also drawn attention to Cabio Biotech , a China-based company that supplies ARA oil, a fatty acid used mainly in infant formula and food products. Several brands said they pulled products after alerts tied to ingredients from the supplier. Cabio Biotech has not publicly responded to claims that its ingredient may be contaminated. Sources Yahoo, Feb. 2, 2026

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047. Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé). Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position. The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position. PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period. PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase. Pressrelease As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047. Johan Lund has been appointed Chairman of the Board, bringing over 25 years of leadership in drug discovery and development from companies such as AstraZeneca and Pfizer. Karin Rosén also joins the Board, adding more than 20 years of global experience in clinical development and medical affairs from companies including Amgen (Horizon), GSK, Genentech (Roche) and Aimmune (Nestlé). Johan Dighed, Helen Pettersson, David Kendall and Anthony Ford were re-elected to the Board. In line with general practice, CEO Per von Mentzer will also step down from his Board position. The company’s Founder and Scientific Advisor Bengt von Mentzer stepped down from the Board as part of the renewal process and will continue to be closely involved in the scientific development of PN6047. In line with general practice, CEO Per von Mentzer will also step down from his Board position. PharmNovo would like to thank Göran Lerenius, who has served as Chairman of the Board since 2017, for his valuable contributions and leadership during this period. PharmNovo looks forward to working with the newly elected Board as the company continues its development and preparations for the next phase. Pressrelease

Korab Zuka, Global Head of Social Impact & Chief Sustainability Officer, Novartis This week's top healthcare stories include Nestlé's product recalls, Novo Nordisk's 2026 predictions and Cera's AI agent for healthcare professionals Nestlé Recalls SMA Formula Over Cereulide Toxin Risk Nestlé has initiated a voluntary recall of certain batches of its SMA Infant Formula and Follow-On Formula in the UK and Ireland due to a potential presence of the toxin cereulide. The company is offering full refunds for returned products. “There have been no confirmed reports of any illness associated with consumption of the products concerned,” Nestlé states. “Nevertheless, out of an abundance of caution, Nestlé has decided to perform this voluntary product recall in line with our strict product quality and safety protocols.” What Does 2026 Have in Store for Novo Nordisk? Mike Doustdar, CEO of Novo Nordisk For global pharmaceutical company Novo Nordisk , 2026 holds a lot of potential. As it works on bouncing back from last year’s setbacks, it aims to grow its presence in the US weight loss market. Novo Nordisk’s CEO, Mike Doustdar, reflected on the year on LinkedIn and shared the company’s plans for the future, including improving its performance and building trust with patients, partners and investors. How Can Cera’s Healthcare AI Aid Nurses, Hospitals & Carers? Cera , the home healthcare innovator, is developing a suite of AI care agents. The agents are designed to automate time-consuming tasks, make decisions based on information they gather and act on them by using reasoning, planning and memory. Cera is set to introduce almost 1,000 agents across its 10,000-strong workforce, speeding up recruitment of carers, organising replacement cover and continuously reviewing and improving patient care quality and compliance. Korab Zuka: Leading Sustainability at Novartis Novartis, one of the world’s largest pharmaceutical companies, has sharpened its sustainability focus under the leadership of Korab Zuka, who took the role of Global Head of Social Impact and Chief Sustainability Officer at the end of 2024. Korab, who joined Novartis a year ago, brings a career shaped by social impact work in both the public and private sectors. His role unites sustainability, access to medicine and the company’s philanthropic foundations under one strategy. For Korab, sustainability is about more than environmental targets. It is intrinsically tied to human health and to Novartis’ mission of widening access to its scientific breakthroughs. As he puts it: “In order for people to have healthy lives, you have to have a healthy planet.” Fujitsu and Nvidia: Harnessing AI to Transform Healthcare Japan's ageing population crisis has inspired an ambitious partnership between Fujitsu and Nvidia, aimed at revolutionising healthcare delivery through artificial intelligence. The collaboration centres on developing a healthcare orchestrator platform that coordinates multiple AI agents to streamline administrative tasks, allowing medical professionals to focus on patient care. With Japan having the world's highest percentage of people over 65, the healthcare system faces mounting pressure on resources and staff. Fujitsu, generating approximately US$24.64bn in revenue last fiscal year with a global workforce of 113,000, has identified healthcare AI as a critical growth sector within its broader strategy to address societal challenges. Company portals Cera Fujitsu Nestlé Novartis Novo Nordisk NVIDIA Executives Dr. Ben Maruthappu Founder & CEO Jensen Huang Founder and CEO Korab Zuka Global Head of Social Impact and Chief Sustainability Officer Maziar Mike Doustdar President and CEO Philipp Navratil Chief Executive Officer